Firm filed registration covering a public offering of 4.9 mil. common shares, and an equal number of share purchase rights. The shares are issuable upon conversion and/or redemption of the $250 mil. principal amount of 6% senior subordinated debentures issued by the company on Oct. 1. Shares are valued at $51.25 each. Company said a portion of the net proceeds from the sale of the debentures has been used, and the remaining proceeds will be used to repay some of the debt incurred with the USV/Armour acquisition.
You may also be interested in...
A lack of regulatory harmonization for dietary supplements in Asia is a big challenge facing companies operating in the region, according to experts from the Asia Regulatory Professionals Association. The ARPA is looking to start a conversation on the issue which the association hopes will lead to regulatory change.
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.
Company is confident that data readout from pivotal trial could be ready before the end of 2020.